{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T15:07:47Z","timestamp":1791990467693,"version":"4.4.0"},"reference-count":41,"publisher":"Oxford University Press (OUP)","funder":[{"DOI":"10.13039\/100000030","name":"Centers for Disease Control and Prevention","doi-asserted-by":"publisher","award":["21IPA2111845"],"award-info":[{"award-number":["21IPA2111845"]}],"id":[{"id":"10.13039\/100000030","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["1F31AI174773-01"],"award-info":[{"award-number":["1F31AI174773-01"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>In 2022\u20132023, 15- and 20-valent pneumococcal conjugate vaccines (PCV15\/PCV20) were recommended for infants. We aimed to estimate the incidence of outpatient visits and antibiotic prescriptions in US children (\u226417 years) from 2016\u20132019 for acute otitis media, pneumonia, and sinusitis associated with PCV15- and PCV20-additional (non-PCV13) serotypes to quantify PCV15\/20 potential impacts.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We estimated the incidence of PCV15\/20-additional serotype-attributable visits and antibiotic prescriptions as the product of all-cause incidence rates, derived from national health care surveys and MarketScan databases, and PCV15\/20-additional serotype-attributable fractions. We estimated serotype-specific attributable fractions using modified vaccine-probe approaches incorporating incidence changes post-PCV13 and ratios of PCV13 versus PCV15\/20 serotype frequencies, estimated through meta-analyses.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Per 1000 children annually, PCV15-additional serotypes accounted for an estimated 2.7 (95% confidence interval, 1.8\u20133.9) visits and 2.4 (95% CI, 1.6\u20133.4) antibiotic prescriptions. PCV20-additional serotypes resulted in 15.0 (95% CI, 11.2\u201320.4) visits and 13.2 (95% CI, 9.9\u201318.0) antibiotic prescriptions annually per 1000 children. PCV15\/20-additional serotypes account for 0.4% (95% CI, 0.2%\u20130.6%) and 2.1% (95% CI, 1.5%\u20133.0%) of pediatric outpatient antibiotic use.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Compared with PCV15-additional serotypes, PCV20-additional serotypes account for &amp;gt; 5 times the burden of visits and antibiotic prescriptions. Higher-valency PCVs, especially PCV20, may contribute to preventing pediatric pneumococcal respiratory infections and antibiotic use.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/infdis\/jiae142","type":"journal-article","created":{"date-parts":[[2024,3,15]],"date-time":"2024-03-15T02:55:54Z","timestamp":1710471354000},"source":"Crossref","is-referenced-by-count":11,"title":["Outpatient Visits and Antibiotic Use Due to Higher-Valency Pneumococcal Vaccine Serotypes"],"prefix":"10.1093","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7785-4712","authenticated-orcid":false,"given":"Laura M","family":"King","sequence":"first","affiliation":[{"name":"School of Public Health, University of California , Berkeley, California , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristin L","family":"Andrejko","sequence":"additional","affiliation":[{"name":"Division of Bacterial Diseases, Centers for Disease Control and Prevention , Atlanta, Georgia , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Kabbani","sequence":"additional","affiliation":[{"name":"Division of Healthcare Quality Promotion, Centers for Disease Control and Prevention , Atlanta, Georgia , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2336-8476","authenticated-orcid":false,"given":"Sara Y","family":"Tartof","sequence":"additional","affiliation":[{"name":"Department of Research and Evaluation, Southern California, Kaiser Permanente , Pasadena, California , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lauri A","family":"Hicks","sequence":"additional","affiliation":[{"name":"Division of Healthcare Quality Promotion, Centers for Disease Control and Prevention , Atlanta, Georgia , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam L","family":"Cohen","sequence":"additional","affiliation":[{"name":"Division of Bacterial Diseases, Centers for Disease Control and Prevention , Atlanta, Georgia , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miwako","family":"Kobayashi","sequence":"additional","affiliation":[{"name":"Division of Bacterial Diseases, Centers for Disease Control and Prevention , Atlanta, Georgia , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph A","family":"Lewnard","sequence":"additional","affiliation":[{"name":"School of Public Health, University of California , Berkeley, California , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2024,3,18]]},"reference":[{"key":"2024040414382381900_jiae142-B1","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1001\/jamapediatrics.2019.5509","article-title":"Trends in pediatric primary care visits among commercially insured US children, 2008-2016","volume":"174","author":"Ray","year":"2020","journal-title":"JAMA Pediatr"},{"key":"2024040414382381900_jiae142-B2","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1185\/03007995.2015.1062355","article-title":"Impact of cough and common cold on productivity, absenteeism, and daily life in the United States: ACHOO survey","volume":"31","author":"Dicpinigaitis","year":"2015","journal-title":"Curr Med Res Opin"},{"key":"2024040414382381900_jiae142-B3","doi-asserted-by":"crossref","first-page":"1864","DOI":"10.1001\/jama.2016.4151","article-title":"Prevalence of inappropriate antibiotic prescriptions among US ambulatory care visits, 2010\u20132011","volume":"315","author":"Fleming-Dutra","year":"2016","journal-title":"JAMA"},{"key":"2024040414382381900_jiae142-B4","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1017\/ash.2021.230","article-title":"Changes in outpatient antibiotic prescribing for acute respiratory illnesses, 2011 to 2018","volume":"1","author":"King","year":"2021","journal-title":"Antimicrob Steward Healthc Epidemiol"},{"key":"2024040414382381900_jiae142-B5","first-page":"133","article-title":"Unnecessary antibiotic prescribing in US ambulatory care settings, 2010\u20132015","volume":"72","author":"Hersh","year":"2021","journal-title":"Clin Infect Dis"},{"key":"2024040414382381900_jiae142-B6","first-page":"258","article-title":"Licensure of a 13-valent pneumococcal conjugate vaccine (PCV13) and recommendations for use among children\u2014advisory committee on immunization practices (ACIP), 2010","volume":"59","author":"Centers for Disease Control and Prevention","year":"2010","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"2024040414382381900_jiae142-B7","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1001\/jamapediatrics.2013.3924","article-title":"Trends in otitis media-related health care use in the United States, 2001\u20132011","volume":"168","author":"Marom","year":"2014","journal-title":"JAMA Pediatr"},{"key":"2024040414382381900_jiae142-B8","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/j.ijporl.2019.01.023","article-title":"National impact of 13-valent pneumococcal conjugate vaccine on ambulatory care visits for otitis media in children under 5\u202fyears in the United States","volume":"119","author":"Zhou","year":"2019","journal-title":"Int J Pediatr Otorhinolaryngol"},{"key":"2024040414382381900_jiae142-B9","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1542\/peds.2007-0619","article-title":"Trends in acute otitis media-related health care utilization by privately insured young children in the United States, 1997\u20132004","volume":"121","author":"Zhou","year":"2008","journal-title":"Pediatrics"},{"key":"2024040414382381900_jiae142-B10","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/j.jpeds.2018.05.047","article-title":"Ambulatory visits for otitis media before and after the introduction of pneumococcal conjugate vaccination","volume":"201","author":"Kawai","year":"2018","journal-title":"J Pediatr"},{"key":"2024040414382381900_jiae142-B11","doi-asserted-by":"crossref","first-page":"7479","DOI":"10.1016\/j.vaccine.2018.10.060","article-title":"Acute otitis media, antimicrobial prescriptions, and medical expenses among children in the United States during 2011\u20132016","volume":"36","author":"Suaya","year":"2018","journal-title":"Vaccine"},{"key":"2024040414382381900_jiae142-B12","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1542\/peds.2006-0492","article-title":"National impact of universal childhood immunization with pneumococcal conjugate vaccine on outpatient medical care visits in the United States","volume":"118","author":"Grijalva","year":"2006","journal-title":"Pediatrics"},{"key":"2024040414382381900_jiae142-B13","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1542\/peds.2003-0592-F","article-title":"Population-based impact of pneumococcal conjugate vaccine in young children","volume":"114","author":"Poehling","year":"2004","journal-title":"Pediatrics"},{"key":"2024040414382381900_jiae142-B14","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1097\/01.inf.0000136871.51792.19","article-title":"Changes in frequency and pathogens causing acute otitis media in 1995\u20132003","volume":"23","author":"Casey","year":"2004","journal-title":"Pediatr Infect Dis J"},{"key":"2024040414382381900_jiae142-B15","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1080\/14760584.2023.2162506","article-title":"Acute otitis media pneumococcal disease burden and nasopharyngeal colonization in children due to serotypes included and not included in current and new pneumococcal conjugate vaccines","volume":"22","author":"Pichichero","year":"2023","journal-title":"Expert Rev Vaccines"},{"key":"2024040414382381900_jiae142-B16","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1186\/s12913-018-3139-1","article-title":"Trends in healthcare utilization and costs associated with acute otitis media in the United States during 2008\u20132014","volume":"18","author":"Tong","year":"2018","journal-title":"BMC Health Serv Res"},{"key":"2024040414382381900_jiae142-B17","doi-asserted-by":"crossref","first-page":"1174","DOI":"10.15585\/mmwr.mm7137a3","article-title":"Use of 15-valent pneumococcal conjugate vaccine among U.S. children: updated recommendations of the advisory committee on immunization practices\u2014United States, 2022","volume":"71","author":"Kobayashi","year":"2022","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"2024040414382381900_jiae142-B18","author":"Centers for Disease Control and Prevention"},{"key":"2024040414382381900_jiae142-B19","author":"Gierke"},{"key":"2024040414382381900_jiae142-B20","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1086\/313608","article-title":"Which pneumococcal serogroups cause the most invasive disease: implications for conjugate vaccine formulation and use, Part I","volume":"30","author":"Hausdorff","year":"2000","journal-title":"Clin Infect Dis"},{"key":"2024040414382381900_jiae142-B21","author":"Centers for Disease Control and Prevention"},{"key":"2024040414382381900_jiae142-B22","doi-asserted-by":"crossref","first-page":"3398","DOI":"10.1016\/j.vaccine.2011.02.088","article-title":"Healthcare utilization and cost of pneumococcal disease in the United States","volume":"29","author":"Huang","year":"2011","journal-title":"Vaccine"},{"key":"2024040414382381900_jiae142-B23","doi-asserted-by":"crossref","first-page":"6483","DOI":"10.1016\/j.vaccine.2009.08.045","article-title":"Cost-effectiveness of pneumococcal conjugate vaccine: an update after 7 years of use in the United States","volume":"27","author":"Ray","year":"2009","journal-title":"Vaccine"},{"key":"2024040414382381900_jiae142-B24","doi-asserted-by":"crossref","first-page":"2914","DOI":"10.1016\/j.vaccine.2023.03.045","article-title":"Public health impact and cost-effectiveness of 15-valent pneumococcal conjugate vaccine use among the pediatric population of the United States","volume":"41","author":"Prasad","year":"2023","journal-title":"Vaccine"},{"key":"2024040414382381900_jiae142-B25","doi-asserted-by":"crossref","first-page":"e1011","DOI":"10.1093\/cid\/ciab062","article-title":"Leveraging vaccines to reduce antibiotic use and prevent antimicrobial resistance: a world health organization action framework","volume":"73","author":"Vekemans","year":"2021","journal-title":"Clin Infect Dis"},{"key":"2024040414382381900_jiae142-B26","doi-asserted-by":"crossref","first-page":"e262","DOI":"10.1542\/peds.2013-1071","article-title":"Clinical practice guideline for the diagnosis and management of acute bacterial sinusitis in children aged 1 to 18 years","volume":"132","author":"Wald","year":"2013","journal-title":"Pediatrics"},{"key":"2024040414382381900_jiae142-B27","doi-asserted-by":"crossref","first-page":"e72","DOI":"10.1093\/cid\/cis370","article-title":"IDSA clinical practice guideline for acute bacterial rhinosinusitis in children and adults","volume":"54","author":"Chow","year":"2012","journal-title":"Clin Infect Dis"},{"key":"2024040414382381900_jiae142-B28","author":"Centers for Disease Control and Prevention"},{"key":"2024040414382381900_jiae142-B29","doi-asserted-by":"crossref","first-page":"1762","DOI":"10.1016\/S0140-6736(13)61682-7","article-title":"Use of vaccines as probes to define disease burden","volume":"383","author":"Feikin","year":"2014","journal-title":"Lancet"},{"key":"2024040414382381900_jiae142-B30","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1093\/cid\/ciw347","article-title":"Impact of widespread Introduction of pneumococcal conjugate vaccines on pneumococcal and nonpneumococcal Otitis Media","volume":"63","author":"Ben-Shimol","year":"2016","journal-title":"Clin Infect Dis"},{"key":"2024040414382381900_jiae142-B31","doi-asserted-by":"crossref","first-page":"1639","DOI":"10.1093\/cid\/ciab645","article-title":"Dynamics of invasive pneumococcal disease in Israel in children and adults in the 13-valent pneumococcal conjugate vaccine (PCV13) era: a nationwide prospective surveillance","volume":"74","author":"Ben-Shimol","year":"2022","journal-title":"Clin Infect Dis"},{"key":"2024040414382381900_jiae142-B32","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.15585\/mmwr.mm6539a4","article-title":"Vaccination coverage among children aged 19\u201335 months\u2014United States, 2015","volume":"65","author":"Hill","year":"2016","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"2024040414382381900_jiae142-B33","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1097\/01.inf.0000178072.83531.4f","article-title":"Pneumococcal acute otitis media in relation to pneumococcal nasopharyngeal carriage","volume":"24","author":"Syrj\u00e4nen","year":"2005","journal-title":"Pediatr Infect Dis J"},{"key":"2024040414382381900_jiae142-B34","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1007\/s10096-021-04324-0","article-title":"Dynamic changes in otopathogens colonizing the nasopharynx and causing acute otitis media in children after 13-valent (PCV13) pneumococcal conjugate vaccination during 2015\u20132019","volume":"41","author":"Kaur","year":"2022","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"2024040414382381900_jiae142-B35","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/S1473-3099(20)30173-0","article-title":"Dynamic changes in paediatric invasive pneumococcal disease after sequential switches of conjugate vaccine in Belgium: a national retrospective observational study","volume":"21","author":"Desmet","year":"2021","journal-title":"Lancet Infect Dis"},{"key":"2024040414382381900_jiae142-B36","author":"Centers for Disease Control and Prevention"},{"key":"2024040414382381900_jiae142-B37","doi-asserted-by":"crossref","first-page":"e213","DOI":"10.1016\/S1473-3099(18)30660-1","article-title":"Making sense of differences in pneumococcal serotype replacement","volume":"19","author":"Lewnard","year":"2019","journal-title":"Lancet Infect Dis"},{"key":"2024040414382381900_jiae142-B38","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1186\/1471-2431-10-4","article-title":"Do pneumococcal conjugate vaccines provide any cross-protection against serotype 19A?","volume":"10","author":"Hausdorff","year":"2010","journal-title":"BMC Pediatrics"},{"key":"2024040414382381900_jiae142-B39","doi-asserted-by":"crossref","first-page":"4872","DOI":"10.1016\/j.vaccine.2022.06.041","article-title":"Streptococcus pneumoniae serotype 15B polysaccharide conjugate elicits a cross-functional immune response against serotype 15C but not 15A","volume":"40","author":"Hao","year":"2022","journal-title":"Vaccine"},{"key":"2024040414382381900_jiae142-B40","first-page":"1","article-title":"Prevention of pneumococcal disease among infants and children\u2014use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine\u2014recommendations of the Advisory Committee on Immunization Practices (ACIP)","volume":"59","author":"Nuorti","year":"2010","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"2024040414382381900_jiae142-B41","doi-asserted-by":"crossref","first-page":"1064","DOI":"10.1001\/jama.2023.15503","article-title":"Treatment failure and adverse events after amoxicillin-clavulanate vs amoxicillin for pediatric acute sinusitis","volume":"330","author":"Savage","year":"2023","journal-title":"JAMA"}],"container-title":["The Journal of Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jid\/advance-article-pdf\/doi\/10.1093\/infdis\/jiae142\/57160685\/jiae142.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jid\/advance-article-pdf\/doi\/10.1093\/infdis\/jiae142\/57160685\/jiae142.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,4,4]],"date-time":"2024-04-04T10:55:19Z","timestamp":1712228119000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jid\/advance-article\/doi\/10.1093\/infdis\/jiae142\/7631226"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3,18]]},"references-count":41,"URL":"https:\/\/doi.org\/10.1093\/infdis\/jiae142","relation":{},"ISSN":["0022-1899","1537-6613"],"issn-type":[{"value":"0022-1899","type":"print"},{"value":"1537-6613","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,3,18]]},"article-number":"jiae142"}}